ISSN: 1859 - 2872
The outcomes of surgery for radioactive iodine refractory differentiated thyroid cancer
Main Article Content
Keywords
Abstract
Objective: To evaluate the efficacy of operation for local recurrence of radioactive iodine refractory differentiated thyroid cancer (RAIR DTC). Subject and method: We retrospectively reviewed data from patients with recurrent RAIR DTC who underwent revision operations at 108 Military Central Hospital between December 2018 and November 2021. Result: Of the 98 patients with DTC (86 female, 12 male) enrolled in this study, 76.5% were in initial stages I, according to the American Joint Committee on Cancer Classification. The mean radioactive iodine course and cumulative radioactive iodine dose were 2.7 times and 351.5mCi, respectively. Surgery was performed in 6 (6.1%) patients for thyroid bed recurrence, and 95 (96.9%) for lymph node recurrence. Major complications occurred in 10 (10.2%) patients. 28 (28.6%) patients had excellent responses, 20 (20.4%) patients had indeterminate responses, 42 (42.9%) patients had biochemically incomplete responses, and 8 (8.2%) patients had structurally incomplete responses according to the American Thyroid Association 2015. Conclusion: Surgery is safe and effective for locoregional RAIR DTC recurrence.
Article Details
References
2. Haddad RI, Nasr C, Bischoff L et al (2018) NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw 16(12): 1429-1440.
3. Tuttle M ML, Haugen B, Shah J et al (2017) Thyroid‐Differentiated and Anaplastic Carcinoma - AJCC Cancer Staging Manual. 8th ed. New York City: Springer International Publishing.
4. Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134(5): 536-538.
5. Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid 27(6): 751-756.
6. Onuma AE, Beal EW, Nabhan F et al (2019) Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. Ann Surg Oncol 26(6): 1737-1743.
7. Son MH, Bieu BQ, Ha LN (2016) Value of Dedicated Head and Neck (18)F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative (131)I Whole-body Scan. Asia Ocean J Nucl Med Biol 4(1): 12-18.
8. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. J Clin Endocrinol Metab 102(3): 1020-1031.
9. Dong W, Horiuchi K, Tokumitsu H, Sakamoto, et al (2019) Time-varying pattern of mortality and recurrence from papillary thyroid cancer: Lessons from a long-term follow-up. Thyroid 29(6): 802-808.
10. Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 384(9940): 319-328.
11. Shobab L, Gomes-Lima C, Zeymo A et al (2019) Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer. Thyroid 29(9): 1262-1268.
12. Wierzbicka M, Gurgul E, Wasniewska-Okupniak E, et al (2014) The feasibility and efficacy of secondary neck dissections in thyroid cancer metastases. Eur Arch Otorhinolaryngol 271(4): 795-799.
13. Lee HS, Roh JL, Gong G et al (2015) Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg 39(8): 1943-1950.
14. Rivera-Robledo CG, Velázquez-Fernández D, Pantoja JP et al (2019) Recurrent papillary thyroid carcinoma to the cervical lymph nodes: Outcomes of compartment-oriented lymph node resection. World J Surg 43(11): 2842-2849.
15. Kalaitzidou S, Papadakis G, Sapera A et al (2020) Outcomes of surgery and radioiodine treatment for neck recurrence in papillary thyroid cancer. J buon 25(1): 383-388.
16. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. The Journal of Clinical Endocrinology & Metabolism 102(3): 1020-1031.
17. Onuma AE, Beal EW, Nabhan F et al (2019) Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. Annals of surgical oncology 26(6): 1737-1743.
18. Chiapponi C, Alakus H, Faust M et al (2021) Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer. Endocr Connect 10(9): 1180-1188.
Article Sidebar
